RxDoctor Payments Data

Maria Betancourt

New York, NYNPI 1831282474

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 34.8% of the total. Reporting peaked in 2019 at $780 and has fallen 59.0% since, to $320 in 2021.

$1,647in general payments, 2019–2025

Across 83 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$574
  • Lupin Inc.$262
  • Amgen$232
  • Merck$142
  • Evofem Biosciences, Inc.$83
  • Daiichi Sankyo Inc.$61
  • plus $292 from 10 others
$105,692in research payments, 2019–2025

Across 49 payments — averaging $2156.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$63K
  • Mitsubishi Tanabe Pharma Development America, Inc.$27K
  • Bayer$16K

What the payments were for

  • Food & beverage$1,60898%
  • Education$392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →